NCT05636605 Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
| NCT ID | NCT05636605 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2018-01-01 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Eligibility Criteria
Inclusion Criteria: * Histopathology or hemology diagnostics of lung cancer * Patients have never received any antineoplastic therapy Exclusion Criteria: * Within 5 years or at the same time, there are other active malignancies * Currently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administration * Active autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration * The study was receiving systemic glucocorticoid treatment (excluding local glucocorticoids by nasal spray, inhalation or other means) or any other form of immunosuppressive therapy within 7 days before the first administration; Note: It is allowed to use glucocorticoid with physiological dose (prednisone ≤ 10mg/day or equivalent) * Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Contact & Investigator
Kai Wang, PhD
PRINCIPAL INVESTIGATOR
The Fourth Affiliated Hospital of Zhejiang University
Frequently Asked Questions
Who can join the NCT05636605 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05636605 currently recruiting?
Yes, NCT05636605 is actively recruiting participants. Contact the research team at doctorhuxi@163.com for enrollment information.
Where is the NCT05636605 trial being conducted?
This trial is being conducted at Yiwu, China.
Who is sponsoring the NCT05636605 clinical trial?
NCT05636605 is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. The principal investigator is Kai Wang, PhD at The Fourth Affiliated Hospital of Zhejiang University. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.